Bing Han | Health and Medicine Advances | Best Researcher Award

Dr. Bing Han | Health and Medicine Advances | Best Researcher Award

Postdoctoral Researcher, The First Affiliated Hospital of Zhengzhou University, China

Dr. Bing Han, Professor at The First Affiliated Hospital of Zhengzhou University, China, is an accomplished medical scientist and clinician whose research bridges molecular biology, microbiome science and clinical gastroenterology. He earned his medical degree (M.D.) followed by postdoctoral research training focused on digestive disease mechanisms and microbial interactions, establishing a strong foundation in translational and precision medicine. His primary research interests center on the gut microbiota–host interaction, bile acid metabolism, intestinal inflammation and biomarker discovery for digestive disorders, with emerging interests in microbiome-based therapeutic interventions. Over his distinguished career, Dr. Bing Han has held academic and clinical roles at The First Affiliated Hospital of Zhengzhou University and collaborated with The First Affiliated Hospital of the University of Science and Technology of China, contributing to interdisciplinary advancements in medical research. His key scientific contributions include innovative studies on the mechanisms of fecal microbiota transplantation in improving inflammatory bowel disease (IBD) and the development of biomedical devices such as spinal positioning systems and femoral defect fixation stents. He has published 9 scientific documents, receiving 50 citations with an h-index of 5 and authored the academic book Frontiers of Tumor Research. Among his notable research supports are the China Postdoctoral Science Foundation Grant, National Natural Science Foundation of China Grant and the Guangxi Natural Science Foundation and Health Commission Projects of Guangxi Zhuang Autonomous Region. His professional engagements include serving as a Young Editorial Board Member for the Journal of Guangxi Medical University and membership in the Digestive Professional Committee of the Chinese Society of Pathophysiology and the Gut Microbiota Branch of the Chinese Society of Biophysics. Through his pioneering research on gut microbiota and digestive pathophysiology, Dr. Bing Han aims to revolutionize clinical diagnostics and therapeutics, promoting global health advancement and innovation in biomedical science.

Profile: Scopus | ORCID | ResearchGate

Featured Publications

1. Han, B., Tang, D., Zhu, H., et al. (2024). Integrated multi-omics reveal gut microbiota-mediated bile acid metabolism regulating immunotherapy responses to anti-α4β7-integrin in Crohn’s disease. Gut Microbes, 16(1), 2310894.

2. Han, B., Li, C., Meng, H., et al. (2019). Efficacy and safety of external-beam radiation therapy for hepatocellular carcinoma: An overview of current evidence according to the different target population. Bioscience Trends, 13(1), 10–22.

3. Han, B., Tang, D., Lv, X., et al. (2023). Comparative efficacy and safety of combination therapy with infliximab for Crohn’s disease: A systematic review and network meta-analysis. International Journal of Colorectal Disease, 38(1), 82.

4. Han, B., Shao, L., Li, C., et al. (2019). Surgery versus external beam radiation therapy for AJCC stage I hepatocellular carcinoma. Journal of BUON, 24(4), 1390–1401.

5. Han, B., Yao, H., Shao, L., et al. (2018). Selection of treatment modalities for hepatocellular carcinoma at stages T1 and T2: A preliminary analysis based on the Surveillance, Epidemiology, and End Results registry database. Journal of BUON, 23(3), 611–621.

 

Ningning Song | Microbiology | Best Researcher Award

Prof. Dr. Ningning Song | Microbiology | Best Researcher Award

Ningning Song at Shandong Second Medical University, China.

Dr. Ningning Song is a distinguished microbiologist specializing in bacterial transcriptional regulation and tuberculosis pathogenesis. She has made significant contributions to identifying regulatory proteins involved in the latent and dormant infection stages of M. tuberculosis. Her research on small molecules affecting transcriptional regulation has provided valuable insights into tuberculosis treatment and drug development. Dr. Song has been instrumental in fostering interdisciplinary collaborations, securing patents, and leading pioneering studies in molecular diagnostics.

Publication Profile

Scopus

Educational Details

Dr. Ningning Song holds a Ph.D. in Molecular Biology, specializing in UVB research, from Belgium. Her academic expertise lies in microbiology, with a strong emphasis on transcriptional regulation, bacterial pathogenesis, and molecular diagnostics.

Professional Experience

Dr. Song is a Professor and the leader of the Young Talent Education Innovation Team of Shandong Province. She serves as a Special Expert under the Weifang Yuandu Scholars program and is the Director of the Weifang Key Laboratory of Respiratory Pathogens and Drug Therapy. Over her career, she has successfully led four National Natural Science Foundation projects, published more than 40 research articles, secured six authorized patents, and contributed to two major talent development projects. As an editorial board member for Frontiers in Cellular and Infection Microbiology, she plays a key role in advancing research in her field.

Research Interest

Dr. Song’s research focuses on the transcriptional regulation of Mycobacterium tuberculosis, omics-based screening of virulence factors, and molecular diagnosis of tuberculosis. Her work extends to exploring nanomaterial-based drug delivery systems for drug-resistant bacteria in collaboration with Tianjin University and investigating regulatory mechanisms of M. tuberculosis with the Chinese Academy of Agricultural Sciences.

Author Metrics & Achievements

    • Total Research Publications: 42 (SCI, Scopus)

    • Completed/Ongoing Research Projects: 9

    • Patents Published/Under Process: 9

    • Books Published (ISBN): 2

    • Editorial Appointments: Frontiers in Cellular and Infection Microbiology

    • Collaborations: Co-published five articles with Tianjin University and the Chinese Academy of Agricultural Sciences

    • Professional Memberships: Chinese Association for the Defense of Tuberculosis

Top Noted Publication

  • Engineered Nanovesicles for the Precise and Noninvasive Treatment of Deep Osteomyelitis Caused by MRSA Infection with Enhanced Immune Response
    Authors: Xingyue Yang, Ren Fang, Xiaotian Li, Yumiao Zhang, Ningning Song
    Journal: ACS Applied Materials & Interfaces, 2025
    Summary: This study introduces engineered nanovesicles designed for the targeted and noninvasive treatment of deep osteomyelitis caused by MRSA infections. The nanovesicles enhance the immune response, offering a promising therapeutic strategy for challenging bone infections.

  • Novel Target and Cofactor Repertoire for the Transcriptional Regulator JTY_0672 from Mycobacterium bovis BCG
    Authors: Hui Wang, Xiaotian Li, Shuxian Wang, Zhaoli Li, Ningning Song
    Journal: Frontiers in Microbiology, 2024
    Summary: This research identifies new targets and cofactors associated with the transcriptional regulator JTY_0672 in Mycobacterium bovis BCG. The findings provide insights into the bacterial transcriptional regulation mechanisms, contributing to the understanding of mycobacterial gene expression.

Conclusion

Dr. Ningning Song is a highly accomplished microbiologist whose contributions to bacterial transcriptional regulation, tuberculosis pathogenesis, and nanomaterial-based drug delivery make her a strong candidate for the Best Researcher Award. Her strong publication record, leadership roles, patents, and interdisciplinary collaborations position her as a leading researcher in her field. Addressing citation impact, global collaborations, and industry applications could further solidify her standing among top researchers worldwide.